Dendrite Announces Schering-Plough to Enhance Sales Force Effectiveness and Business Planning Solution With Dendrite's Proven .
June 30 2006 - 3:43PM
Business Wire
Dendrite International, Inc. (NASDAQ:DRTE), a leading provider of
pharmaceutical industry solutions, today announced that Schering
Corporation, a subsidiary of Schering-Plough Corporation, has
signed a five-year agreement to enhance VISION, its proprietary
sales force effectiveness (SFE) and business planning solution, for
its U.S.-based pharmaceutical field sales organization. As a
result, Dendrite will seamlessly integrate components of its proven
.NET framework with Schering-Plough's VISION system to facilitate
the sales force in managing customer information and recording call
activity. Dendrite's .NET framework provides compelling capability
to make sales representatives and managers more efficient and
productive in their selling activities. Field sales organizations
can benefit from Dendrite's revolutionary system navigation, built
on human-centered design principles that mirror the workflow of the
representative. By matching sales force tools to workflow,
representatives can maximize the number of prescriber visits and
the quality of each prescriber interaction. Augmenting the expanded
capabilities of Schering-Plough's VISION system will be Sample
Guardian(TM), Dendrite's integrated home office sample management
and reconciliation solution. Pharmaceutical companies benefit from
having a flexible and cost effective alternative for tracking,
analyzing, reporting, and storing all drug sample activity data.
Sample Guardian, and associated custom reports developed together
with Dendrite, assists pharmaceutical companies with ongoing
efforts to comply with Food and Drug Administration (FDA) and
Prescription Drug Marketing Act (PDMA) regulations. "Leveraging
Dendrite for pharma-specific business process enhancements will
give Schering-Plough access to the latest and most effective
technologies, proven methodologies and best practices, and support
through highly trained personnel with extensive pharmaceutical
experience, allowing for continued focus on their core business of
developing therapies and having a positive impact on patient
lives," said Natasha Giordano, president of global accounts for
Dendrite. About Dendrite Founded in 1986, Dendrite International
(NASDAQ:DRTE) enables sales, marketing, clinical and compliance
solutions for the global pharmaceutical industry. The Company's
clients are located in more than 50 countries and include the
world's top 20 pharmaceutical companies. For more information,
please visit www.dendrite.com. Note: Dendrite is a registered
trademark of Dendrite International, Inc. This document may contain
forward-looking statements that may be identified by such
forward-looking terminology as "expect," "believe," "anticipate,"
"will," "intend," "plan," "target," "outlook," "guidance," and
similar statements or variations. Such forward-looking statements
are based on our current expectations, estimates, assumptions and
projections and involve significant risks and uncertainties,
including risks which may result from our dependence on the
pharmaceutical industry; fluctuations in quarterly revenues due to
lengthy sales and implementation cycles for certain of our
solutions; our fixed expenses in relation to fluctuating revenues
and variations in customers' budget cycles; dependence on certain
major customers; changes in demand for our products and services
attributable to any weakness experienced in the economy or mergers,
acquisitions and consolidations in the pharmaceutical industry;
successful and timely development and introduction of new products
and versions; rapid technological changes; increased competition;
international operations; integrating the entities we acquire; our
ability to effectively manage our growth; the protection of our
proprietary technology; our ability to compete in the
Internet-related products and services market; the continued demand
for Internet-related products and services; the ability of our
third party vendors to respond to technological change; our ability
to maintain our relationships with third-party vendors; less
favorable than anticipated results from strategic relationships;
dependence of data solutions on strategic relationships; events
which may affect the U.S. and world economies; and catastrophic
events which could negatively affect our information technology
infrastructure. Other important factors that should be reviewed and
carefully considered are included in the company's 10-K, 10-Qs, and
other reports filed with the SEC. Actual results may differ
materially. The company assumes no obligation for updating any such
forward-looking statements to reflect actual results, changes in
assumptions or other changes affecting such forward-looking
statements and the information provided in this press release
should not be construed as updating, modifying or confirming the
company's most recent financial outlook or guidance.
Dendrite (NASDAQ:DRTE)
Historical Stock Chart
From May 2024 to Jun 2024
Dendrite (NASDAQ:DRTE)
Historical Stock Chart
From Jun 2023 to Jun 2024